Recent developments in Leishmaniasis: Epidemiology, diagnosis, and treatment
Tóm tắt
Từ khóa
Tài liệu tham khảo
Irajhi AA, Ibrahim EA, De Vol EB, et al.: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002, 346:891–895. This is the first randomized, controlled study that shows that an oral agent is effective for one form of cutaneous leishmaniasis (that caused by L. major).
Herwaldt BL, Arana BA, Navin TR: The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992, 165:518–527.
Navin TR, Arana BA, Arana FE, et al.: Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992, 165:528–534.
Velez I, Agudelo S, Hendrickx E, et al.: Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 1997, 126:232–236.
Desjeux P: Worldwide increasing risk factors for leishmaniasis. Med Microbiol Immunol 2001, 190:77–79.
Reithinger R, Mohsen H, Aadil K, et al.: Anthroponotic cutaneous leishmaniasis Kabul, Afghanistan. Emerg Infect Dis 2003, 9:727–729. This paper describes the largest present outbreak of leishmaniasis.
Centers for Disease Control and Prevention: Update: cutaneous leishmaniasis in US military personnel--Southwest/ Central Asia, 2002–2004. MMWR Morb Mortal Wkly Rep 2004, 53:264–265. This article describes the largest outbreak of leishmaniasis in US personnel in the past 50 years.
Davies CR, Reithinger R, Campbell-Lendrum D, et al.: The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 2000, 16:925–950.
Ramirez JR, Adugelo S, Muskus C, et al.: Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitological diagnosis. J Clin Microbiol 2000, 38:3768–3773.
Weigle KA, Iabrada LA, Lozano C, et al.: PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (viannia). J Clin Microbiol 2002, 40:601–606.
de Oliveira CI, Bafica A, Oliveira F, et al.: Clinical utility of polymerase chain reaction-based detection of Leishmania in the diagnosis of American cutaneous leishmaniasis. Clin Infect Dis 2003, 37:e149-e153.
Rodrigues EH, Felinto de Brito ME, Mendonca MG, et al.: Evaluation of PCR for diagnosis of American cutaneous leishmaniasis in an area of endemicity in northeastern Brazil. J Clin Microbiol 2002, 40:3572–3576.
Faber WR, Oskam L, van Gool T, et al.: Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol 2003, 49:70–74.
Mendonca MG, de Brito ME, Rodrigues EH, et al.: Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004, 189:1018–1023.
Thakur CP, Kanyok TP, Pandey AK, et al.: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000, 94:432–433.
Veeken H, Ritmeijer K, Seaman J, Davidson R: A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000, 5:312–317.
Moore E, O’Flaherty D, Heuvelmans H, et al.: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001, 79:388–393.
Ritmeijer K, Veeken H, Melaku Y, et al.: Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001, 95:668–672.
Sundar S, Jha TK, Thakur CP, et al.: Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002, 66:143–146.
Sundar S, Jha TK, Thakur CP, et al.: Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002, 347:1739–1746. This paper details the most significant advance in antileishmanial therapy in the past 10 years—the first effective oral agent for visceral leishmaniasis, at least in India.
Bhattacharya SK, Jha TK, Sundar S, et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004, 38:217–221.
Romero GA, Guerra MV, Paes MG, Macedo VO: Comparison of cutaneous leishmaniasis due to L. braziliensis and L. guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001, 65:456–465.
Machado, P, Araujo C, da Silva AT, et al.: Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002, 34:e69-e73.
Palacios R, Osorio LE, Grajalew LF, Ochoa MT: Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001, 64:187–193.
Wortmann G, Miller RS, Oster C, et al.: A randomized, doubleblind study of the efficacy of a 10-or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002, 35:261–267.
Soto JM, Toledo JT, Gutierrez P, et al.: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002, 66:147–151.
Arana BA, Mendoza CE, Rizzo NR, Kroeger A: Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001, 65:466–470.
Soto J, Fuya P, Herrera R, Berman J: Topical paromomycin/MBCL plus parenteral meglumine in the treatment of American cutaneous leishmaniasis: a controlled study. Clin Infect Dis 1998, 26:56–58.
Soto J, Toledo J, Gutierrez P, et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001, 33:E57-E61.